KIF11 and neoplasm: Eg5 could be a new valid biomarker to be added in the panel of protein markers and to be analyzed by immunohistochemistry after tumor tissue biopsy: high rates of Eg5 expression could modify the therapeutic approach, with the possibility to add an Eg5 inhibitor to the standard therapy.